Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
2.
Aust Vet J ; 97(3): 75-80, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30809814

RESUMO

BACKGROUND: Cefovecin has a long duration of antibiotic activity in cats and dogs, somewhat attributable to its high plasma protein binding. AIMS: To determine the cefovecin binding to plasma proteins in vitro in selected Australian marsupials and to quantify the change in cetovecin concentration over time following subcutaneous injection in koalas. METHODS AND RESULTS: Various cefovecin concentrations were incubated with plasma and quantified using HPLC. The median (range) bound percentages when 10 µg/mL of cefovecin was incubated with plasma were 11.1 (4.1-20.4) in the plasma of the Tasmanian devil, 12.7 (5.8-17.3) in the koala, 18.9 (14.6-38.0) in the eastern grey kangaroo, 16.9 (15.7-30.2) in the common brush-tailed possum, 37.6 (25.3-42.3) in the eastern ring-tailed possum and 36.4 (35.0-38.3) in the red kangaroo, suggesting that cefovecin may have a shorter duration of action in these species than in cats and dogs. Cefovecin binding to plasma proteins in thawed, frozen equine plasma was also undertaken for assay quality control and the median (range) plasma protein binding (at 10 µg/mL) was 95.6% (94.9-96.6%). Cefovecin was also administered to six koalas at 8 mg/kg subcutaneously and serial blood samples were collected at 3, 6, 24, 48, 72, 96 h thereafter. Cefovecin plasma concentrations were not quantifiable in four koalas and in the other two, the mean plasma concentration at t = 3 h was 1.04 ± 0.01 µg/mL. CONCLUSION: Because of the limited pharmacokinetic data generated, no further pharmacokinetic analysis was performed; however, a single injected bolus of cefovecin is likely to have a short duration of action in koalas (hours, rather than days).


Assuntos
Antibacterianos/metabolismo , Proteínas Sanguíneas/metabolismo , Cefalosporinas/metabolismo , Marsupiais/sangue , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Austrália , Cefalosporinas/administração & dosagem , Cefalosporinas/farmacocinética , Cromatografia Líquida de Alta Pressão/veterinária , Feminino , Técnicas In Vitro , Injeções Subcutâneas/veterinária , Masculino , Marsupiais/metabolismo , Phascolarctidae/sangue , Phascolarctidae/metabolismo
3.
J Vet Pharmacol Ther ; 41(1): 1-10, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28703410

RESUMO

Although koalas are iconic Australian animals, no pharmacokinetic studies of any first-line medicines used to treat diseased or injured koalas had been published prior to 2010. Traditionally, medicine dosages suggested for this species underwent linear extrapolation from those recommended for domesticated species. The koala, a specialist folivore whose natural diet consists of almost exclusively Eucalyptus spp. foliage has anatomical and physiological adaptations for detoxifying their diet which also affect medicine pharmacokinetic profiles. This review addresses aspects of medicine absorption, clearance, and other indices (such as medicine binding to plasma proteins) of enrofloxacin/marbofloxacin and chloramphenicol used for the systemic treatment of chlamydiosis, and fluconazole ± amphotericin, and posaconazole for the treatment of cryptococcosis. Based on observations from published studies, this review includes suggestions to improve therapeutic outcomes when administering medicines to diseased koalas.


Assuntos
Anti-Infecciosos/farmacocinética , Phascolarctidae , Animais , Antibacterianos/farmacocinética , Antifúngicos/farmacocinética , Phascolarctidae/anatomia & histologia , Phascolarctidae/metabolismo , Phascolarctidae/fisiologia , Xenobióticos/farmacocinética
4.
Aust Vet J ; 95(9): 343-349, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28845567

RESUMO

OBJECTIVE: Because of limited availability of chloramphenicol to veterinary suppliers, a preliminary study was performed to predict whether an analogue, florfenicol, is an efficacious treatment for chlamydiosis in koalas. METHODS: Florfenicol was administered to koalas with naturally occurring chlamydiosis at 20 mg/kg SC (n = 3) and at 5 mg/kg (n = 3) and 10 mg/kg (n = 3) IV. The estimated areas under the plasma concentration versus time curves (AUC) were compared with the minimum inhibitory concentration to inhibit Chlamydia pecorum. Clinical data were also examined from field trials conducted on koalas (n = 19) with naturally occurring chlamydiosis and treated with florfenicol at a range of dosages (5-20 mg/kg SC and 6-15 mg/kg IV). Florfenicol binding to proteins in plasma was also determined. RESULTS: Florfenicol was not detectable in plasma 24 h post-administration at 20 mg/kg SC. The estimated AUC0-24 h following administration at 10 mg/kg IV suggests florfenicol might be effective against Chlamydia spp. via this route. Florfenicol binding to plasma proteins was 13.0% (± 0.30 SEM). After treatment with florfenicol in field trials, 5 of 19 koalas (26%) were released without further treatment, 4 with no long-term follow-up; 6 (32%) required additional treatment with chloramphenicol to resolve chlamydiosis; 7 (36%) failed to clinically improve, of which 3 had clinical signs and/or necropsy findings suggestive of antibiotic-related gastrointestinal dysbiosis; another koala died within minutes of florfenicol administered IV at 7 mg/kg. CONCLUSION: When administered at dosages tolerable in the field, florfenicol is a problematic treatment for chlamydiosis based on equivocal outcomes and plasma concentrations below those that inhibit the pathogen.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Chlamydia/veterinária , Phascolarctidae , Tianfenicol/análogos & derivados , Animais , Chlamydia , Infecções por Chlamydia/tratamento farmacológico , Feminino , Masculino , Tianfenicol/uso terapêutico , Resultado do Tratamento
5.
J Vet Pharmacol Ther ; 40(6): 675-681, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28455999

RESUMO

The pharmacokinetic profile of posaconazole in clinically normal koalas (n = 8) was investigated. Single doses of posaconazole were administered intravenously (i.v.; 3 mg/kg; n = 2) or orally (p.o.; 6 mg/kg; n = 6) with serial plasma samples collected over 24 and 36 hr, respectively. Plasma concentrations of posaconazole were quantified by validated high-performance liquid chromatography. A noncompartmental pharmacokinetic analysis of data was performed. Following i.v. administration, estimates of the median (range) of plasma clearance (CL) and steady-state volume of distribution (Vss ) were 0.15 (0.13-0.18) L hr-1  kg-1 and 1.23 (0.93-1.53) L/kg, respectively. The median (range) elimination half-life (t1/2 ) after i.v. and p.o. administration was 7.90 (7.62-8.18) and 12.79 (11.22-16.24) hr, respectively. Oral bioavailability varied from 0.43 to 0.99 (median: 0.66). Following oral administration, maximum plasma concentration (Cmax ; median: 0.72, range: 0.55-0.93 µg/ml) was achieved in 8 (range 6-12) hr. The in vitro plasma protein binding of posaconazole incubated at 37°C was 99.25 ± 0.29%. Consideration of posaconazole pharmacokinetic/pharmacodynamic (PK/PD) targets for some yeasts such as disseminated candidiasis suggests that posaconazole could be an efficacious treatment for cryptococcosis in koalas.


Assuntos
Antifúngicos/farmacocinética , Phascolarctidae/metabolismo , Triazóis/farmacocinética , Administração Oral , Animais , Antifúngicos/administração & dosagem , Antifúngicos/sangue , Cromatografia Líquida de Alta Pressão/veterinária , Feminino , Injeções Intravenosas/veterinária , Triazóis/administração & dosagem , Triazóis/sangue
6.
J Vet Pharmacol Ther ; 39(4): 412-5, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26667113

RESUMO

Three asymptomatic koalas serologically positive for cryptococcosis and two symptomatic koalas were treated with 10 mg/kg fluconazole orally, twice daily for at least 2 weeks. The median plasma Cmax and AUC0-8 h for asymptomatic animals were 0.9 µg/mL and 4.9 µg/mL·h, respectively; and for symptomatic animals 3.2 µg/mL and 17.3 µg/mL·h, respectively. An additional symptomatic koala was treated with fluconazole (10 mg/kg twice daily) and a subcutaneous amphotericin B infusion twice weekly. After 2 weeks the fluconazole Cmax was 3.7 µg/mL and the AUC0-8 h was 25.8 µg/mL*h. An additional three koalas were treated with fluconazole 15 mg/kg twice daily for at least 2 weeks, with the same subcutaneous amphotericin protocol co-administered to two of these koalas (Cmax : 5.0 µg/mL; mean AUC0-8 h : 18.1 µg/mL*h). For all koalas, the fluconazole plasma Cmax failed to reach the MIC90 (16 µg/mL) to inhibit C. gattii. Fluconazole administered orally at either 10 or 15 mg/kg twice daily in conjunction with amphotericin is unlikely to attain therapeutic plasma concentrations. Suggestions to improve treatment of systemic cryptococcosis include testing pathogen susceptibility to fluconazole, monitoring plasma fluconazole concentrations, and administration of 20-25 mg/kg fluconazole orally, twice daily, with an amphotericin subcutaneous infusion twice weekly.


Assuntos
Antifúngicos/farmacocinética , Criptococose/veterinária , Fluconazol/farmacocinética , Phascolarctidae/microbiologia , Administração Oral , Animais , Antifúngicos/administração & dosagem , Antifúngicos/sangue , Antifúngicos/uso terapêutico , Criptococose/tratamento farmacológico , Feminino , Fluconazol/administração & dosagem , Fluconazol/sangue , Fluconazol/uso terapêutico , Masculino , Phascolarctidae/sangue , Phascolarctidae/metabolismo
7.
Aust Vet J ; 93(11): 420-3, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26412342

RESUMO

OBJECTIVE: To determine the in vitro susceptibilities of koala isolates of Chlamydia pecorum to enrofloxacin and chloramphenicol, which are frequently used to treat koalas with chlamydiosis, and florfenicol, a derivative of chloramphenicol. METHODS: The in vitro susceptibilities were determined by culturing three stored isolates and seven clinical swabs of C. pecorum. Susceptibility testing was undertaken using cycloheximide-treated buffalo green monkey kidney cells in 96 well microtitre plates. RESULTS: The minimum inhibitory concentrations (MICs) for all isolates were 0.25-0.50 µg/mL (enrofloxacin), 1-2 µg/mL (chloramphenicol), and 1-2 µg/mL (florfenicol). Minimum bactericidal concentration (MBC) values for five isolates were also determined and were within one two-fold dilution of MICs. The MICs and MBCs of these antimicrobials were within ranges previously reported for other chlamydial species. CONCLUSION: When combined with previously published pharmacokinetic data, the in vitro susceptibility results support chloramphenicol as a more appropriate treatment option than enrofloxacin for koalas with chlamydiosis. The susceptibility results also indicate florfenicol may be an appropriate treatment option for koalas with chlamydiosis, warranting further investigation.


Assuntos
Antibacterianos/farmacologia , Antineoplásicos/farmacologia , Chlamydia/efeitos dos fármacos , Cloranfenicol/farmacologia , Fluoroquinolonas/farmacologia , Tianfenicol/análogos & derivados , Animais , Infecções por Chlamydia/tratamento farmacológico , Infecções por Chlamydia/veterinária , Chlorocebus aethiops , Enrofloxacina , Técnicas In Vitro , Testes de Sensibilidade Microbiana , Phascolarctidae , Tianfenicol/farmacologia
8.
Aust Vet J ; 93(1-2): 40-5, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25622709

RESUMO

OBJECTIVES: To investigate whether selected drug combinations used to treat rapidly growing mycobacteria (RGM) have drug-drug interactions that affect efficacy and to investigate each isolate's susceptibility to cefovecin and clofazimine, individually. DESIGN: In vitro susceptibility testing of bacterial isolates. METHODS: Initially, five feline isolates and one canine isolate from both Mycobacterium fortuitum and M. smegmatis clusters (n = 12) underwent microbroth susceptibility testing to individual drugs to establish minimum inhibitory concentrations (MIC) of cefovecin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, enrofloxacin, trimethoprim and sulfanilamide (the latter two as a combination). Checkerboard assays were then performed for susceptible M. smegmatis isolates for the following combinations: clarithromycin (one isolate only) versus enrofloxacin, clarithromycin vs doxycycline, clarithromycin vs trimethoprim/sulfanilamide; enrofloxacin vs doxycycline (six isolates); enrofloxacin vs trimethoprim/sulfanilamide (six isolates). Susceptible M. fortuitum isolates were tested against enrofloxacin versus doxycycline (four isolates only). RESULTS: All six M. fortuitum isolates were susceptible to enrofloxacin, but only four of six were susceptible to doxycycline. All six M. smegmatis isolates were susceptible to doxycycline, enrofloxacin and trimethoprim/sulfanilamide. A single isolate from the 12, a M. smegmatis isolate, was susceptible to clarithromycin. The fractional inhibitory concentration of each drug ranged from 0.64 to 1.84, indicating that neither synergism nor antagonism was evident. All 12 isolates were resistant to cefovecin. The clofazimine MIC50 to inhibit isolate growth was approximately 3.3 µg/mL for both strains. CONCLUSION: Drugs commonly used for treatment of RGM, when tested as combinations, do not appear to antagonise one another in vitro. Cefovecin is not efficacious for treatment of RGM infections.


Assuntos
Antibacterianos/farmacologia , Cefalosporinas/farmacologia , Clofazimina/farmacologia , Mycobacterium fortuitum/efeitos dos fármacos , Mycobacterium smegmatis/efeitos dos fármacos , Animais , Anti-Inflamatórios , Doenças do Gato/tratamento farmacológico , Gatos , Ciprofloxacina/farmacologia , Claritromicina/farmacologia , Doenças do Cão/tratamento farmacológico , Cães , Doxiciclina/farmacologia , Combinação de Medicamentos , Farmacorresistência Bacteriana , Enrofloxacina , Fluoroquinolonas/farmacologia , Técnicas In Vitro , Testes de Sensibilidade Microbiana/veterinária , Infecções por Mycobacterium/tratamento farmacológico , Infecções por Mycobacterium/veterinária , Staphylococcus aureus/efeitos dos fármacos , Sulfanilamida , Sulfanilamidas/farmacologia , Trimetoprima/farmacologia
9.
J Vet Pharmacol Ther ; 37(3): 301-11, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24219009

RESUMO

Clinically normal koalas (n = 6) received a single dose of intravenous enrofloxacin (10 mg/kg). Serial plasma samples were collected over 24 h, and enrofloxacin concentrations were determined via high-performance liquid chromatography. Population pharmacokinetic modeling was performed in S-ADAPT. The probability of target attainment (PTA) was predicted via Monte Carlo simulations (MCS) using relevant target values (30-300) based on the unbound area under the curve over 24 h divided by the minimum inhibitory concentration (MIC) (fAUC0-24 /MIC), and published subcutaneous data were incorporated (Griffith et al., 2010). A two-compartment disposition model with allometrically scaled clearances (exponent: 0.75) and volumes of distribution (exponent: 1.0) adequately described the disposition of enrofloxacin. For 5.4 kg koalas (average weight), point estimates for total clearance (SE%) were 2.58 L/h (15%), central volume of distribution 0.249 L (14%), and peripheral volume 2.77 L (20%). MCS using a target fAUC0-24 /MIC of 40 predicted highest treatable MICs of 0.0625 mg/L for intravenous dosing and 0.0313 mg/L for subcutaneous dosing of 10 mg/kg enrofloxacin every 24 h. Thus, the frequently used dosage of 10 mg/kg enrofloxacin every 24 h subcutaneously may be appropriate against gram-positive bacteria with MICs ≤ 0.03 mg/L (PTA > 90%), but appears inadequate against gram-negative bacteria and Chlamydiae in koalas.


Assuntos
Antibacterianos/farmacologia , Antibacterianos/farmacocinética , Fluoroquinolonas/farmacologia , Fluoroquinolonas/farmacocinética , Phascolarctidae/metabolismo , Animais , Antibacterianos/metabolismo , Área Sob a Curva , Ciprofloxacina/sangue , Ciprofloxacina/metabolismo , Ciprofloxacina/farmacocinética , Enrofloxacina , Feminino , Fluoroquinolonas/metabolismo , Meia-Vida , Masculino , Testes de Sensibilidade Microbiana , Modelos Biológicos , Método de Monte Carlo , Phascolarctidae/sangue , Especificidade da Espécie
10.
J Vet Pharmacol Ther ; 37(1): 90-8, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23889092

RESUMO

Clinically normal koalas (n = 12) received a single dose of 10 mg/kg fluconazole orally (p.o.; n = 6) or intravenously (i.v.; n = 6). Serial plasma samples were collected over 24 h, and fluconazole concentrations were determined using a validated HPLC assay. A noncompartmental pharmacokinetic analysis was performed. Following i.v. administration, median (range) plasma clearance (CL) and steady-state volume of distribution (Vss ) were 0.31 (0.11-0.55) L/h/kg and 0.92 (0.38-1.40) L/kg, respectively. The elimination half-life (t1/2 ) was much shorter than in many species (i.v.: median 2.25, range 0.98-6.51 h; p.o.: 4.69, range 2.47-8.01 h), and oral bioavailability was low and variable (median 0.53, range 0.20-0.97). Absorption rate-limited disposition was evident. Plasma protein binding was 39.5 ± 3.5%. Although fluconazole volume of distribution (Varea ) displayed an allometric relationship with other mammals, CL and t1/2 did not. Allometrically scaled values were approximately sevenfold lower (CL) and sixfold higher (t1/2 ) than observed values, highlighting flaws associated with this technique in physiologically distinct species. On the basis of fAUC/MIC pharmacodynamic targets, fluconazole is predicted to be ineffective against Cryptococcus gattii in the koala as a sole therapeutic agent administered at 10 mg/kg p.o. every 12 h.


Assuntos
Antifúngicos/farmacocinética , Fluconazol/farmacocinética , Phascolarctidae/sangue , Administração Oral , Animais , Antifúngicos/administração & dosagem , Antifúngicos/sangue , Fluconazol/administração & dosagem , Fluconazol/sangue , Injeções Intravenosas/veterinária , Phascolarctidae/metabolismo
11.
Artigo em Inglês | MEDLINE | ID: mdl-24345479

RESUMO

Quantitative and qualitative aspects of in vitro metabolism of the non-steroidal anti-inflammatory drug meloxicam, mediated via hepatic microsomes of specialized foliage (Eucalyptus) eating marsupials (koalas and ringtail possums), a generalized foliage eating marsupial (brushtail possum), rats, and dogs, are described. Using a substrate depletion method, intrinsic hepatic clearance (in vitro Clint) was determined. Significantly, rates of oxidative transformation of meloxicam, likely mediated via cytochromes P450 (CYP), were higher in marsupials compared to rats or dogs. The rank order of apparent in vitro Clint was brushtail possums (n=3) (mean: 394µL/min/mg protein), >koalas (n=6) (50), >ringtail possums (n=2) (36) (with no significant difference between koalas and ringtail possums), >pooled rats (3.2)>pooled dogs (in which the rate of depletion, as calculated by the ratio of the substrate remaining was <20% and too slow to determine). During the depletion of meloxicam, at a first-order rate constant, 5-hydroxymethyl metabolite (M1) was identified in the brushtail possums and the rat as the major metabolite. However, multiple hydroxyl metabolites were observed in the koala (M1, M2, and M3) and the ringtail possum (M1 and M3) indicating that these specialized foliage-eating marsupials have diverse oxidation capacity to metabolize meloxicam. Using a well-stirred model, the apparent in vitro Clint of meloxicam for koalas and the rat was further scaled to compare with published in vivo Cl. The closest in vivo Cl prediction from in vitro data of koalas was demonstrated with scaled hepatic Cl(total) (average fold error=1.9) excluding unbound fractions in the blood and microsome values; whereas for rats, the in-vitro scaled hepatic Cl fu(blood, mic), corrected with unbound fractions in the blood and microsome values, provided the best prediction (fold error=1.86). This study indicates that eutherians such as rats or dogs serve as inadequate models for dosage extrapolation of this drug to marsupials due to differences in hepatic turnover rate. Furthermore, as in vivo Cl is one of the pharmacokinetic indexes for determining therapeutic drug dosages, this study demonstrates the utility of in vitro to in vivo scaling as an alternative prediction method of drug Cl in koalas.


Assuntos
Microssomos Hepáticos/metabolismo , Phascolarctidae/metabolismo , Tiazinas/metabolismo , Tiazóis/metabolismo , Trichosurus/metabolismo , Animais , Cães , Masculino , Meloxicam , Ratos , Ratos Sprague-Dawley/metabolismo
12.
Aust Vet J ; 91(5): 171-8, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23614511

RESUMO

OBJECTIVES: To investigate in vitro susceptibilities of canine and feline Escherichia coli and canine Pseudomonas spp. isolates to ticarcillin and ticarcillin-clavulanic acid (T/C). DESIGN: In vitro susceptibility testing of bacterial isolates collected from infections. METHODS: We tested 148 (83 canine and 65 feline) E. coli and 61 canine Pseudomonas spp. isolates for susceptibility to T/C using both disc diffusion and Epsilometer tests (E-tests). Additionally, susceptibilities of 96 E. coli and 23 canine Pseudomonas spp. isolates were tested via disc diffusion to ticarcillin alone. RESULTS: Of the E. coli isolates obtained from canine and feline urine, 92% by disc diffusion and 91% by E-tests were susceptible to T/C. Of the canine Pseudomonas isolates, 90% by disc diffusion and 82% by E-tests were susceptible to T/C. Of the Pseudomonas spp. isolates from the canine ear canal or tympanic bullae, 12% of isolates tested via disc diffusion and 23% via E-tests were found to be resistant to T/C. The 50% minimum inhibitory concentration of T/C for all feline E. coli isolates was significantly lower than that for all canine E. coli isolates (P = 0.0031). The addition of clavulanic acid significantly increased the efficacy of ticarcillin against E. coli (P< 0.0001), but had negligible effect against canine Pseudomonas spp. isolates. CONCLUSION: Ticarcillin-clavulanic acid has reasonable in vitro efficacy against canine and feline E. coli, and canine Pseudomonas spp. isolates. However, decisions to use this drug therapeutically must be made on prudent considerations to minimise selection for bacterial resistance.


Assuntos
Antibacterianos/farmacologia , Escherichia coli/efeitos dos fármacos , Testes de Sensibilidade Microbiana/veterinária , Pseudomonas/efeitos dos fármacos , Ticarcilina/farmacologia , Animais , Doenças do Gato/tratamento farmacológico , Doenças do Gato/microbiologia , Gatos , Ácidos Clavulânicos/farmacologia , Contagem de Colônia Microbiana/veterinária , Doenças do Cão/tratamento farmacológico , Doenças do Cão/microbiologia , Cães , Relação Dose-Resposta a Droga , Farmacorresistência Bacteriana , Testes de Sensibilidade Microbiana/métodos , Resultado do Tratamento
13.
J Vet Pharmacol Ther ; 36(5): 486-93, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23406022

RESUMO

The pharmacokinetic profile of meloxicam in clinically healthy koalas (n = 15) was investigated. Single doses of meloxicam were administered intravenously (i.v.) (0.4 mg/kg; n = 5), subcutaneously (s.c.) (0.2 mg/kg; n = 1) or orally (0.2 mg/kg; n = 3), and multiple doses were administered to two groups of koalas via the oral or s.c. routes (n = 3 for both routes) with a loading dose of 0.2 mg/kg for day 1 followed by 0.1 mg/kg s.i.d for a further 3 days. Plasma meloxicam concentrations were quantified by high-performance liquid chromatography. Following i.v. administration, meloxicam exhibited a rapid clearance (CL) of 0.44 ± 0.20 (SD) L/h/kg, a volume of distribution at terminal phase (Vz ) of 0.72 ± 0.22 L/kg and a volume of distribution at steady state (Vss ) of 0.22 ± 0.12 L/kg. Median plasma terminal half-life (t(1/2)) was 1.19 h (range 0.71-1.62 h). Following oral administration either from single or repeated doses, only maximum peak plasma concentration (C(max) 0.013 ± 0.001 and 0.014 ± 0.001 µg/mL, respectively) was measurable [limit of quantitation (LOQ) >0.01 µg/mL] between 4-8 h. Oral bioavailability was negligible in koalas. Plasma protein binding of meloxicam was ~98%. Three meloxicam metabolites were detected in plasma with one identified as the 5-hydroxy methyl derivative. This study demonstrated that koalas exhibited rapid CL and extremely poor oral bioavailability compared with other eutherian species. Accordingly, the currently recommended dose regimen of meloxicam for this species appears inadequate.


Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Phascolarctidae/metabolismo , Tiazinas/farmacocinética , Tiazóis/farmacocinética , Administração Oral , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/sangue , Cromatografia Líquida de Alta Pressão/métodos , Cromatografia Líquida de Alta Pressão/veterinária , Cromatografia de Fase Reversa/métodos , Cromatografia de Fase Reversa/veterinária , Feminino , Injeções Intravenosas/veterinária , Injeções Subcutâneas/veterinária , Masculino , Meloxicam , Phascolarctidae/sangue , Tiazinas/administração & dosagem , Tiazinas/sangue , Tiazóis/administração & dosagem , Tiazóis/sangue
14.
J Vet Pharmacol Ther ; 36(5): 478-85, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23157306

RESUMO

Clinically normal koalas (n = 19) received a single dose of intravenous (i.v.) chloramphenicol sodium succinate (SS) (25 mg/kg; n = 6), subcutaneous (s.c.) chloramphenicol SS (60 mg/kg; n = 7) or s.c. chloramphenicol base (60 mg/kg; n = 6). Serial plasma samples were collected over 24-48 h, and chloramphenicol concentrations were determined using a validated high-performance liquid chromatography assay. The median (range) apparent clearance (CL/F) and elimination half-life (t(1/2)) of chloramphenicol after i.v. chloramphenicol SS administration were 0.52 (0.35-0.99) L/h/kg and 1.13 (0.76-1.40) h, respectively. Although the area under the concentration-time curve was comparable for the two s.c. formulations, the absorption rate-limited disposition of chloramphenicol base resulted in a lower median C(max) (2.52; range 0.75-6.80 µg/mL) and longer median tmax (8.00; range 4.00-12.00 h) than chloramphenicol SS (C(max) 20.37, range 13.88-25.15 µg/mL; t(max) 1.25, range 1.00-2.00 h). When these results were compared with susceptibility data for human Chlamydia isolates, the expected efficacy of the current chloramphenicol dosing regimen used in koalas to treat chlamydiosis remains uncertain and at odds with clinical observations.


Assuntos
Antibacterianos/farmacocinética , Cloranfenicol/análogos & derivados , Cloranfenicol/farmacocinética , Phascolarctidae/metabolismo , Animais , Antibacterianos/administração & dosagem , Cloranfenicol/administração & dosagem , Cloranfenicol/sangue , Cromatografia Líquida de Alta Pressão , Feminino , Injeções Intravenosas/veterinária , Injeções Subcutâneas/veterinária , Masculino , Phascolarctidae/sangue
15.
J Vet Pharmacol Ther ; 35(2): 147-54, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21569052

RESUMO

Nine mature koalas with chlamydiosis, typically keratoconjunctivitis and/or urogenital tract infection, were treated with daily subcutaneous injections of chloramphenicol at 60 mg/kg for 45 days (five koalas), or for a shorter duration (four koalas). All koalas were initially positive for Chlamydia pecorum as determined by real-time polymerase chain reaction (qPCR). Plasma chloramphenicol concentrations were determined at t = 0, 1, 2, 4, 8, and 24 h after the day 1 injection (nine koalas) and after the day 15 injection (seven koalas). Chloramphenicol reached a median (and range) maximum plasma concentration of 3.03 (1.32-5.03 µg/mL) at 4 (1-8 h) after the day 1 injection and 4.82 (1.97-27.55 µg/mL) at 1 (1-2 h) after day 15. The median (and range) of AUC(0-24) on day 1 and day 15 were 48.14 (22.37-81.14 µg·h/mL) and 50.83 (28.43-123.99 µg·h/mL), respectively. The area under the moment curve (AUMC)(0-24) median (and range) for day 1 and day 15 were 530.03 (233.05-798.97 h) and 458.15 (291.72-1093.58 h), respectively. Swabs were positive for chlamydial DNA pretreatment, and all koalas except one, produced swabs negative for chlamydial DNA during treatment and which remained so, for 2-63 days after treatment, however whether chloramphenicol treatment prevented long-term recrudescence of infection was not established. At this dose and dosing frequency, chloramphenicol appeared to control mild chlamydial infection and prevent shedding, but severe urogenital disease did not appear to respond to chloramphenicol at this dosage regime. For koalas affected by severe chlamydiosis, antibiotics alone are not sufficient to effect a cure, possibly because of structural or metabolic changes associated with chronic disease and inflammation.


Assuntos
Antibacterianos/farmacocinética , Antibacterianos/uso terapêutico , Infecções por Chlamydia/veterinária , Cloranfenicol/farmacocinética , Cloranfenicol/uso terapêutico , Phascolarctidae/sangue , Animais , Animais Selvagens , Área Sob a Curva , Infecções por Chlamydia/tratamento farmacológico , Feminino , Masculino
16.
Vet Microbiol ; 153(3-4): 240-5, 2011 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-21726965

RESUMO

Rapidly growing mycobacteria (RGM) and Nocardiae can cause severe or refractory infections in cats and dogs. Prolonged antibacterial therapy is required to cure these infections. As fluoroquinolones have been used in combination therapy for treating RGM infections, isolates from the Mycobacterium smegmatis cluster (n=64), Mycobacterium fortuitum cluster (n=17), and M. mageritense cluster (n=2), collected from feline and canine patients, underwent susceptibility testing to pradofloxacin. The MIC(50), MIC(90) and tentative epidemiological cut-off (ECOFF) values as determined by microbroth dilution susceptibility testing that inhibited growth of the M. smegmatis and M. fortuitum clusters were 0.063, 0.125 and ≤ 0.25; and 0.125, 0.250 and ≤ 1.0 µg/mL, respectively. E-Test results showed similar trends but MICs were lower than those for microbroth dilution. In summary, pradofloxacin demonstrated effective in vitro activity against RGM isolates. Additionally, veterinary isolates of Nocardia nova (n=18), Nocardia farcinica (n=3) and Nocardia cyriacigeorgica (n=1) underwent microbroth dilution testing to ciprofloxacin, enrofloxacin and pradofloxacin. The MIC(50) and MIC(90) of pradofloxacin, ciprofloxacin and enrofloxacin that inhibited growth of Nocardia nova isolates were 2 (4), 8 (16), 16 (32) µg/mL, respectively. The tentative ECOFF values for pradofloxacin and ciprofloxacin were 32 µg/mL and for enrofloxacin 64 µg/mL. The MIC or MIC range for the three N. farcinica isolates of pradofloxacin, ciprofloxacin and enrofloxacin were 0.25-0.5, 2 and 2 µg/mL and for the single N. cyriacigeorgica isolate were 1, 4 and 4 µg/mL, respectively. On the basis on these results, fluoroquinolones appear to have limited therapeutic potential for most Nocardia infections.


Assuntos
Doenças do Gato/microbiologia , Doenças do Cão/microbiologia , Fluoroquinolonas/farmacologia , Infecções por Mycobacterium/veterinária , Mycobacterium/efeitos dos fármacos , Nocardiose/veterinária , Nocardia/efeitos dos fármacos , Animais , Antibacterianos/farmacologia , Gatos , Ciprofloxacina/farmacologia , Cães , Enrofloxacina , Testes de Sensibilidade Microbiana/veterinária , Mycobacterium/crescimento & desenvolvimento , Infecções por Mycobacterium/microbiologia , Nocardia/crescimento & desenvolvimento , Nocardiose/microbiologia
17.
Vet Microbiol ; 147(1-2): 113-8, 2011 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-20619975

RESUMO

Rapidly growing mycobacteria (RGM) cause infections in cats and dogs which require prolonged antibacterial medication for resolution. In Australia, pathogens from the Mycobacterium fortuitum and Mycobacterium smegmatis clusters are responsible for most of the RGM infections in cats and dogs. As fluoroquinolones are often recommended for treating such infections, 14 M. fortuitum isolates, 51 isolates from the M. smegmatis cluster and 2 M. mageritense isolates, collected from feline and canine patients, underwent susceptibility testing to the second generation fluoroquinolones ciprofloxacin and enrofloxacin and the newer generation fluoroquinolone moxifloxacin. Using microbroth dilution, the MIC(90) of ciprofloxacin, enrofloxacin, and moxifloxacin that inhibited growth of M. fortuitum isolates were 0.500, 0.250 and 0.063 µg/mL respectively. For the M. smegmatis cluster isolates the corresponding MIC(90) was 0.500, 0.250 and 0.125 µg/mL respectively. E-test results showed similar trends but MICs were lower than those determined by microbroth dilution. Additionally, moxifloxacin was administered to 10 clinically normal cats (50mg per cat, once daily for 4 days). The plasma moxifloxacin concentration 2h after the last dose was determined by liquid chromatography as 2.2 ± 0.6 µg/mL. The plasma concentration at 2h:MIC(90) ratios for moxifloxacin for M. fortuitum and M. smegmatis cluster was 34.9 and 17.6 respectively which exceeded the recommended threshold of 10, indicating that moxifloxacin has good theoretical efficacy for treatment of those M. fortuitum and M. smegmatis infections in cats and dogs that have become refractory to other antibacterial drug classes.


Assuntos
Antibacterianos/farmacologia , Fluoroquinolonas/farmacologia , Mycobacterium/efeitos dos fármacos , Animais , Antibacterianos/efeitos adversos , Antibacterianos/sangue , Antibacterianos/farmacocinética , Austrália , Compostos Aza/efeitos adversos , Compostos Aza/sangue , Compostos Aza/farmacocinética , Gatos , Ciprofloxacina/farmacologia , Diarreia/induzido quimicamente , Diarreia/veterinária , Cães , Enrofloxacina , Feminino , Fluoroquinolonas/efeitos adversos , Fluoroquinolonas/sangue , Fluoroquinolonas/farmacocinética , Masculino , Testes de Sensibilidade Microbiana/veterinária , Moxifloxacina , Mycobacterium/isolamento & purificação , Quinolinas/efeitos adversos , Quinolinas/sangue , Quinolinas/farmacocinética
18.
J Vet Pharmacol Ther ; 33(6): 595-604, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21062313

RESUMO

Koalas (n = 43) were treated daily for up to 8 weeks with enrofloxacin: 10 mg/kg subcutaneously (s.c.), 5 mg/kg s.c., or 20 mg/kg per os (p.o.); or marbofloxacin: 1.0-3.3 mg/kg p.o., 10 mg/kg p.o. or 5 mg/kg s.c. Serial plasma drug concentrations were determined on day 1 and again at approximately 2 weeks, by liquid chromatography. The median (range) plasma maximum concentrations (C(max) ) for enrofloxacin 5 mg/kg s.c. and 10 mg/kg s.c. were 0.83 (0.68-1.52) and 2.08 (1.34-2.96) µg/mL and the median (range) T(max) were 1.5 h (1-2) and 1 h (1-2) respectively. Plasma concentrations of orally dosed marbofloxacin were too low to be quantified. Oral administration of enrofloxacin suggested absorption rate limited disposition pharmacokinetics; the median (range) C(max) for enrofloxacin 20 mg/kg p.o. was 0.94 (0.76-1.0) µg/mL and the median (range) T(max) was 4 h (2-8). Oral absorption of both drugs was poor. Plasma protein binding for enrofloxacin was 55.4 ± 1.9% and marbofloxacin 49.5 ± 5.3%. Elevations in creatinine kinase activity were associated with drug injections. Enrofloxacin and marbofloxacin administered at these dosage and routes are unlikely to inhibit the growth of chlamydial pathogens in vivo.


Assuntos
Antibacterianos/farmacologia , Fluoroquinolonas/farmacologia , Fluoroquinolonas/farmacocinética , Phascolarctidae/metabolismo , Administração Oral , Animais , Antibacterianos/administração & dosagem , Enrofloxacina , Feminino , Fluoroquinolonas/administração & dosagem , Fluoroquinolonas/sangue , Injeções Subcutâneas/veterinária , Absorção Intestinal , Masculino , Phascolarctidae/sangue
19.
Aust Vet J ; 88(5): 197-200, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20529031

RESUMO

A 1-year-old, entire male Tasmanian devil living in captivity was presented because of a nodular inguinal lesion that subsequently developed a draining sinus tract. A second, similar lesion developed later in the ipsilateral axillary region. A deep representative biopsy specimen of abnormal subcutaneous tissue showed chronic active pyogranulomatous inflammation and beaded Gram-positive and acid-fast bacilli situated in lipid vacuoles within the lesion. A rapidly growing Mycobacterium species, shown subsequently to be M. mageritense, was grown from a swab of the primary lesion. It was susceptible to tetracyclines (including doxycycline) and moxifloxacin in vitro. The lesions resolved following treatment with doxycycline monohydrate (50 mg PO once daily) and then moxifloxacin (10 mg/kg PO for 20 days). The infection probably resulted from inoculation of subcutaneous tissues by material containing this Mycobacterium following fight or bite injuries. The presentation is reminiscent of similar lesions attributable to rapidly growing mycobacterial infections of the subcutis observed in domestic cats and quolls.


Assuntos
Marsupiais/microbiologia , Infecções por Mycobacterium/veterinária , Mycobacterium/crescimento & desenvolvimento , Paniculite/veterinária , Tela Subcutânea/microbiologia , Animais , Antibacterianos/uso terapêutico , Compostos Aza/uso terapêutico , Doxiciclina/uso terapêutico , Fluoroquinolonas , Histocitoquímica/veterinária , Masculino , Moxifloxacina , Infecções por Mycobacterium/tratamento farmacológico , Infecções por Mycobacterium/microbiologia , Paniculite/tratamento farmacológico , Paniculite/microbiologia , Quinolinas/uso terapêutico
20.
Aust Vet J ; 87(11): 445-9, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19857237

RESUMO

OBJECTIVE: To identify veterinarians' approaches and concerns when managing canine and feline patients with acute and chronic seizure disorders. DESIGN: Cross-sectional survey. METHOD: A questionnaire was distributed to veterinarians to determine how many dogs and cats they were actively treating for seizures, their anticonvulsant drug (ACD) preferences for treating acute and chronic seizure disorders and whether serum anticonvulsant concentrations and/or biochemical analytes were routinely measured. Additional questions involved the respondent's year and place of graduation and identified concerns they faced when managing patients with seizure disorders. RESULTS: Phenobarbitone was the most commonly used ACD for managing chronic seizure disorders in both dogs and cats, with 82% of respondents using a combination of phenobarbitone and potassium bromide to manage refractory seizure disorders in dogs. Most respondents (96%) felt comfortable managing seizures in dogs, but only 63% were comfortable managing affected cats. Routine monitoring of serum ACD concentrations and of liver biochemical analytes was performed routinely by 71% and 45% of respondents, respectively. Of the respondents, 86% graduated from Australian universities and of these 53% had graduated after 1985. CONCLUSION: Veterinarians identified when to commence medication, whether regular monitoring of serum ACD concentrations and liver enzyme activity was necessary, and if the cost was justified. Veterinarians also identified the need to balance dose rates and side-effects by using combination therapy, and the importance of providing accurate information to clients about what to expect in terms of seizure control for their pet.


Assuntos
Anticonvulsivantes/uso terapêutico , Doenças do Gato/tratamento farmacológico , Doenças do Cão/tratamento farmacológico , Epilepsia/veterinária , Médicos Veterinários/psicologia , Animais , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/metabolismo , Brometos/efeitos adversos , Brometos/metabolismo , Brometos/uso terapêutico , Doenças do Gato/sangue , Gatos , Estudos Transversais , Doenças do Cão/sangue , Cães , Quimioterapia Combinada/veterinária , Epilepsia/sangue , Epilepsia/tratamento farmacológico , Humanos , Fígado/metabolismo , Fenobarbital/efeitos adversos , Fenobarbital/metabolismo , Fenobarbital/uso terapêutico , Compostos de Potássio/efeitos adversos , Compostos de Potássio/metabolismo , Compostos de Potássio/uso terapêutico , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...